Stephen T. Chen Buys 151,000 Shares of Amarillo Biosciences Inc (AMAR) Stock

Amarillo Biosciences Inc (OTCMKTS:AMAR) insider Stephen T. Chen acquired 151,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 14th. The shares were purchased at an average cost of $0.25 per share, with a total value of $37,750.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of OTCMKTS AMAR traded down $0.06 during trading hours on Friday, hitting $0.37. 3,165 shares of the stock were exchanged, compared to its average volume of 6,517. Amarillo Biosciences Inc has a one year low of $0.15 and a one year high of $0.61.

Amarillo Biosciences (OTCMKTS:AMAR) last posted its quarterly earnings data on Wednesday, November 14th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $0.02 million for the quarter.

ILLEGAL ACTIVITY NOTICE: “Stephen T. Chen Buys 151,000 Shares of Amarillo Biosciences Inc (AMAR) Stock” was published by WKRB News and is the property of of WKRB News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at

About Amarillo Biosciences

Amarillo Biosciences, Inc engages in the development of biologics for the treatment of human and animal diseases. The company owns or licenses five issued patents related to the low-dose oral delivery of interferon; and owns one issued patent on its dietary supplement, Maxisal. It focuses on research for the treatment of human disease indications primarily influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon alpha.

Recommended Story: What are no-load funds?

Insider Buying and Selling by Quarter for Amarillo Biosciences (OTCMKTS:AMAR)

Receive News & Ratings for Amarillo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarillo Biosciences and related companies with's FREE daily email newsletter.

Leave a Reply